Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-76
Last updated

Report documents

  1. Extract of dossier assessment

    Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 742 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-76_en
    Download file : Extract of dossier assessment (PDF document, 742 kB, EN, not accessible)

  2. Dossier assessment

    Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-76
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

Adults with progressive metastatic castration resistant prostate cancer (mCRPC): identification of patients with prostate-specific membrane antigen-positive mCRPC for whom prostate-specific membrane antigen-targeted therapy is indicated

Result of dossier assessment:
  • Patients for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or BSC is the individually optimized treatment: indication of major added benefit
  • Patients for whom cabazitaxel or olaparib is the individually optimized treatment: added benefit not proven

Press releases

Prostate cancer: Major added benefit for PSMA diagnostics with gozetotide

Due to the direct link between diagnostics and therapy, the data on the early benefit assessment of the therapeutic agent lutetium-177 can be used for the assessment of gozetotide.
Press release

Project details

Project no.
A24-76
Commission
Commission awarded on 15.07.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Diagnostics
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-76_en

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page